Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

CLDX Stock Forecast

Celldex Therapeutics stock forecast is as follows: an average price target of $61.25 (represents a 162.76% upside from CLDX’s last price of $23.31) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

CLDX Price Target

The average price target for Celldex Therapeutics (CLDX) is $61.25 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $44.00. This represents a potential 162.76% upside from CLDX's last price of $23.31.

CLDX Analyst Ratings

Buy

According to 8 Wall Street analysts, Celldex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CLDX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 3 'Hold' (37.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Celldex Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 29, 2024	Joseph Pantginis	H.C. Wainwright	$80.00	$27.11	195.04%	243.20%
Sep 25, 2024	Derek Archila	Wells Fargo	$44.00	$36.02	22.15%	88.76%
Jun 17, 2024	Alex Thompson	Stifel Nicolaus	$58.00	$34.91	66.14%	148.82%
Nov 10, 2023	Derek Archila	Wells Fargo	$27.00	$25.78	4.73%	15.83%
Nov 11, 2022	-	Guggenheim	$63.00	$39.89	57.93%	170.27%

Row per page

Go to

The latest Celldex Therapeutics stock forecast, released on Oct 29, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $80.00, which represents a 195.04% increase from the stock price at the time of the forecast ($27.11), and a 243.20% increase from CLDX last price ($23.31).

Celldex Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	2	3
Avg Price Target	$80.00	$62.00	$60.67
Last Closing Price	$23.31	$23.31	$23.31
Upside/Downside	243.20%	165.98%	160.27%

In the current month, the average price target of Celldex Therapeutics stock is $80.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 243.20% increase as opposed to Celldex Therapeutics's last price of $23.31. This month's average price target is up 29.03% compared to last quarter, and up 31.86% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 28, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 28, 2024	Wolfe Research	Buy	Buy	Hold
Oct 28, 2024	Wells Fargo	Underperform	Underperform	Hold
Oct 28, 2024	Guggenheim	Buy	Buy	Hold
Oct 07, 2024	Citigroup	-	Buy	Initialise
Sep 30, 2024	Goldman Sachs	-	Neutral	Initialise
Sep 27, 2024	Leerink Partners	-	Market Perform	Downgrade
Sep 26, 2024	Wolfe Research	Buy	Peer Perform	Downgrade
Sep 25, 2024	Guggenheim	Buy	Buy	Hold

Row per page

Go to

Celldex Therapeutics's last stock rating was published by H.C. Wainwright on Oct 29, 2024. The company gave CLDX a "Buy" rating, the same as its previous rate.

Celldex Therapeutics Financial Forecast

Celldex Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$4.13M	$1.52M	$268.00K	$967.00K	$1.61M	$407.00K	$163.00K	$174.00K	$334.00K	$153.00K	$3.48M	$685.00K	$3.79M	$668.00K	$236.00K	$2.73M	$887.00K	$546.00K	$715.00K	$1.43M	$4.07M	$1.53M
Avg Forecast	$650.00K	$433.33K	$433.33K	$433.33K	$1.02M	$835.56K	$854.29K	$809.00K	$1.44M	$583.33K	$528.00K	$410.00K	$264.00K	$360.00K	$400.00K	$560.00K	$1.04M	$1.22M	$643.33K	$965.00K	$600.00K	$395.00K	$800.00K	$990.00K	$815.00K	$1.26M	$1.26M	$1.26M	$978.74K	$1.56M
High Forecast	$1.11M	$740.86K	$740.86K	$433.33K	$1.74M	$1.43M	$854.43K	$1.38M	$1.80M	$583.50K	$902.71K	$700.97K	$451.35K	$360.00K	$400.00K	$560.00K	$1.04M	$1.22M	$643.33K	$965.00K	$600.00K	$395.00K	$800.00K	$990.00K	$815.00K	$1.26M	$1.26M	$1.26M	$1.17M	$1.87M
Low Forecast	$419.35K	$279.57K	$279.57K	$433.33K	$655.91K	$539.07K	$854.14K	$521.93K	$1.07M	$583.17K	$340.64K	$264.52K	$170.32K	$360.00K	$400.00K	$560.00K	$1.04M	$1.22M	$643.33K	$965.00K	$600.00K	$395.00K	$800.00K	$990.00K	$815.00K	$1.26M	$1.26M	$1.26M	$782.99K	$1.25M
# Analysts	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	9
Surprise %	-	-	-	-	-	-	-	-	2.87%	2.60%	0.51%	2.36%	6.11%	1.13%	0.41%	0.31%	0.32%	0.13%	5.41%	0.71%	6.31%	1.69%	0.29%	2.76%	1.09%	0.43%	0.57%	1.13%	4.16%	0.98%

Celldex Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $809.00K, with a low forecast of $521.93K, and a high forecast of $1.38M. CLDX's average Quarter revenue forecast represents a -80.42% decrease compared to the company's last Quarter revenue of $4.13M (Dec 23).

Celldex Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	9
EBITDA	-	-	-	-	-	-	-	-	$-32.17M	$-38.26M	$-30.50M	$-35.58M	$-29.28M	$-27.94M	$-18.70M	$-23.73M	$-20.25M	$-17.02M	$-12.23M	$-15.00M	$3.07M	$-12.28M	$-13.59M	$-11.48M	$-13.75M	$-15.29M	$-13.62M	$-10.65M	$72.90M	$-27.57M
Avg Forecast	$-650.00K	$-433.33K	$-433.33K	$-433.33K	$-1.02M	$-835.56K	$-854.29K	$-17.71M	$-1.44M	$-583.33K	$-528.00K	$-18.95M	$-17.68M	$-360.00K	$-400.00K	$-20.26M	$-1.04M	$-1.22M	$-14.50M	$-965.00K	$-600.00K	$-395.00K	$-800.00K	$-11.14M	$-815.00K	$-1.26M	$-1.26M	$-12.26M	$-228.53M	$-33.28M
High Forecast	$-419.35K	$-279.57K	$-279.57K	$-433.33K	$-655.91K	$-539.07K	$-854.14K	$-14.17M	$-1.07M	$-583.17K	$-340.64K	$-15.16M	$-14.14M	$-360.00K	$-400.00K	$-16.21M	$-1.04M	$-1.22M	$-11.60M	$-965.00K	$-600.00K	$-395.00K	$-800.00K	$-8.91M	$-815.00K	$-1.26M	$-1.26M	$-9.81M	$-182.83M	$-26.63M
Low Forecast	$-1.11M	$-740.86K	$-740.86K	$-433.33K	$-1.74M	$-1.43M	$-854.43K	$-21.26M	$-1.80M	$-583.50K	$-902.71K	$-22.73M	$-21.22M	$-360.00K	$-400.00K	$-24.31M	$-1.04M	$-1.22M	$-17.40M	$-965.00K	$-600.00K	$-395.00K	$-800.00K	$-13.36M	$-815.00K	$-1.26M	$-1.26M	$-14.72M	$-274.24M	$-39.94M
Surprise %	-	-	-	-	-	-	-	-	22.32%	65.59%	57.77%	1.88%	1.66%	77.60%	46.75%	1.17%	19.54%	13.93%	0.84%	15.54%	-5.11%	31.08%	16.98%	1.03%	16.87%	12.14%	10.81%	0.87%	-0.32%	0.83%

2 analysts predict CLDX's average Quarter EBITDA for Mar 21 to be $-965.00K, with a high of $-965.00K and a low of $-965.00K. This is -131.45% lower than Celldex Therapeutics's previous annual EBITDA (Dec 20) of $3.07M.

Celldex Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	9
Net Income	-	-	-	-	-	-	-	-	$-50.25M	$-38.26M	$-30.50M	$-22.41M	$-23.69M	$-24.96M	$-52.57M	$-21.56M	$-19.27M	$-20.45M	$-13.76M	$-17.30M	$-21.90M	$-14.22M	$-11.03M	$-12.61M	$-6.00M	$-11.41M	$-11.78M	$-17.24M	$-118.13M	$-34.26M
Avg Forecast	$-58.01M	$-55.91M	$-56.13M	$-54.14M	$-48.65M	$-44.59M	$-38.97M	$-18.36M	$-48.64M	$-45.08M	$-43.64M	$-19.64M	$-18.39M	$-37.41M	$-30.37M	$-21.00M	$-27.51M	$-23.44M	$-15.38M	$-22.78M	$-24.21M	$-23.77M	$-38.29M	$-12.27M	$-59.42M	$-63.38M	$-77.24M	$-13.31M	$-229.48M	$-34.90M
High Forecast	$-31.25M	$-30.12M	$-30.24M	$-45.92M	$-42.73M	$-24.02M	$-20.99M	$-14.69M	$-35.20M	$-24.28M	$-23.51M	$-15.71M	$-14.71M	$-37.41M	$-30.37M	$-16.80M	$-27.51M	$-23.44M	$-12.30M	$-22.78M	$-24.21M	$-23.77M	$-38.29M	$-9.82M	$-59.42M	$-63.38M	$-77.24M	$-10.65M	$-183.58M	$-27.92M
Low Forecast	$-111.52M	$-107.49M	$-107.91M	$-62.36M	$-57.19M	$-85.72M	$-74.92M	$-22.03M	$-58.24M	$-86.67M	$-83.91M	$-23.56M	$-22.07M	$-37.41M	$-30.37M	$-25.20M	$-27.51M	$-23.44M	$-18.45M	$-22.78M	$-24.21M	$-23.77M	$-38.29M	$-14.72M	$-59.42M	$-63.38M	$-77.24M	$-15.97M	$-275.38M	$-41.88M
Surprise %	-	-	-	-	-	-	-	-	1.03%	0.85%	0.70%	1.14%	1.29%	0.67%	1.73%	1.03%	0.70%	0.87%	0.89%	0.76%	0.90%	0.60%	0.29%	1.03%	0.10%	0.18%	0.15%	1.30%	0.51%	0.98%

Celldex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CLDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Celldex Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	9
SG&A	-	-	-	-	-	-	-	-	$8.83M	$8.22M	$7.22M	$6.64M	$6.60M	$6.53M	$7.15M	$6.91M	$6.24M	$5.82M	$4.31M	$4.12M	$3.62M	$3.64M	$3.53M	$3.67M	$3.22M	$3.40M	$3.91M	$4.90M	$5.59M	$7.23M
Avg Forecast	$3.47M	$2.31M	$2.31M	$2.31M	$5.43M	$4.46M	$4.56M	$4.32M	$7.70M	$3.12M	$2.82M	$2.19M	$1.41M	$1.92M	$2.14M	$2.99M	$5.53M	$6.53M	$3.44M	$5.15M	$3.20M	$2.11M	$4.27M	$5.29M	$4.35M	$6.73M	$6.73M	$6.73M	$5.23M	$8.33M
High Forecast	$5.93M	$3.96M	$3.96M	$2.31M	$9.28M	$7.63M	$4.56M	$7.39M	$9.62M	$3.12M	$4.82M	$3.74M	$2.41M	$1.92M	$2.14M	$2.99M	$5.53M	$6.53M	$3.44M	$5.15M	$3.20M	$2.11M	$4.27M	$5.29M	$4.35M	$6.73M	$6.73M	$6.73M	$6.27M	$9.99M
Low Forecast	$2.24M	$1.49M	$1.49M	$2.31M	$3.50M	$2.88M	$4.56M	$2.79M	$5.71M	$3.11M	$1.82M	$1.41M	$909.54K	$1.92M	$2.14M	$2.99M	$5.53M	$6.53M	$3.44M	$5.15M	$3.20M	$2.11M	$4.27M	$5.29M	$4.35M	$6.73M	$6.73M	$6.73M	$4.18M	$6.66M
Surprise %	-	-	-	-	-	-	-	-	1.15%	2.64%	2.56%	3.03%	4.68%	3.40%	3.35%	2.31%	1.13%	0.89%	1.25%	0.80%	1.13%	1.73%	0.83%	0.69%	0.74%	0.51%	0.58%	0.73%	1.07%	0.87%

Celldex Therapeutics's average Quarter SG&A projection for Mar 24 is $4.32M, based on 2 Wall Street analysts, with a range of $2.79M to $7.39M. The forecast indicates a -51.09% fall compared to CLDX last annual SG&A of $8.83M (Dec 23).

Celldex Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	10	10	10	10	9	9	9	9	20	9
EPS	-	-	-	-	-	-	-	-	$-1.04K	$-0.81	$-0.65	$-0.47	$-0.50	$-0.53	$-1.12	$-0.46	$-0.41	$-0.45	$-0.35	$-0.44	$-0.55	$-0.39	$-0.50	$-0.72	$-0.36	$-0.41	$-0.63	$-1.83	$-12.61	$-4.81
Avg Forecast	$-0.88	$-0.84	$-0.85	$-0.82	$-0.73	$-0.67	$-0.59	$-0.69	$-0.73	$-0.68	$-0.66	$-0.62	$-0.59	$-0.57	$-0.46	$-0.45	$-0.42	$-0.35	$-0.40	$-0.34	$-0.37	$-0.36	$-0.58	$-0.71	$-0.90	$-0.96	$-1.17	$-1.14	$-5.89	$-4.36
High Forecast	$-0.47	$-0.45	$-0.46	$-0.69	$-0.64	$-0.36	$-0.32	$-0.37	$-0.53	$-0.37	$-0.35	$-0.34	$-0.32	$-0.57	$-0.46	$-0.45	$-0.42	$-0.35	$-0.40	$-0.34	$-0.37	$-0.36	$-0.58	$-0.71	$-0.90	$-0.96	$-1.17	$-1.14	$-4.71	$-3.49
Low Forecast	$-1.68	$-1.62	$-1.63	$-0.94	$-0.86	$-1.29	$-1.13	$-1.33	$-0.88	$-1.31	$-1.27	$-1.20	$-1.13	$-0.57	$-0.46	$-0.45	$-0.42	$-0.35	$-0.40	$-0.34	$-0.37	$-0.36	$-0.58	$-0.71	$-0.90	$-0.96	$-1.17	$-1.14	$-7.06	$-5.23
Surprise %	-	-	-	-	-	-	-	-	1413.57%	1.19%	0.99%	0.76%	0.85%	0.94%	2.43%	1.03%	0.98%	1.27%	0.87%	1.28%	1.50%	1.08%	0.86%	1.01%	0.40%	0.43%	0.54%	1.61%	2.14%	1.10%

According to undefined Wall Street analysts, Celldex Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CLDX previous annual EPS of $NaN (undefined).

Celldex Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ALXO	ALX Oncology	$1.22	$24.50	1908.20%	Buy
VTYX	Ventyx Biosciences	$1.77	$33.86	1812.99%	Buy
AVTE	Aerovate Therapeutics	$2.53	$13.00	413.83%	Hold
BCAB	BioAtla	$1.51	$5.00	231.13%	Buy
DAWN	Day One Biopharmaceuticals	$13.01	$38.80	198.23%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
IMTX	Immatics	$7.82	$22.00	181.33%	Buy
ANAB	AnaptysBio	$18.88	$52.00	175.42%	Buy
CLDX	Celldex Therapeutics	$23.31	$61.25	162.76%	Buy
COGT	Cogent Biosciences	$8.99	$18.83	109.45%	Buy
SWTX	SpringWorks Therapeutics	$34.56	$67.33	94.82%	Buy
KROS	Keros Therapeutics	$54.01	$102.60	89.96%	Buy
IDYA	IDEAYA Biosciences	$26.19	$46.58	77.85%	Buy
CYTK	Cytokinetics	$51.94	$83.23	60.24%	Buy
DYN	Dyne Therapeutics	$29.34	$43.88	49.56%	Buy
MGTX	MeiraGTx	$6.09	$9.00	47.78%	Buy
EWTX	Edgewise Therapeutics	$30.79	$45.00	46.15%	Buy
RNA	Avidity Biosciences	$41.35	$54.50	31.80%	Buy
CRNX	Crinetics Pharmaceuticals	$53.70	$70.14	30.61%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
TVTX	Travere Therapeutics	$17.39	$21.75	25.07%	Buy
RVMD	Revolution Medicines, Inc. Warrant	$54.24	$60.63	11.78%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy

CLDX Forecast FAQ

Is Celldex Therapeutics a good buy?

Yes, according to 8 Wall Street analysts, Celldex Therapeutics (CLDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 62.50% of CLDX's total ratings.

What is CLDX's price target?

Celldex Therapeutics (CLDX) average price target is $61.25 with a range of $44 to $80, implying a 162.76% from its last price of $23.31. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Celldex Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CLDX stock, the company can go up by 162.76% (from the last price of $23.31 to the average price target of $61.25), up by 243.20% based on the highest stock price target, and up by 88.76% based on the lowest stock price target.

Can Celldex Therapeutics stock reach $30?

CLDX's average twelve months analyst stock price target of $61.25 supports the claim that Celldex Therapeutics can reach $30 in the near future.

What is Celldex Therapeutics's current price target trend?

1 Wall Street analyst forecast a $80 price target for Celldex Therapeutics (CLDX) this month, up 243.20% from its last price of $23.31. Compared to the last 3 and 12 months, the average price target increased by 165.98% and increased by 160.27%, respectively.

What are Celldex Therapeutics's analysts' financial forecasts?

Celldex Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.52M (high $5.4M, low $2.57M), average EBITDA is $-20.42M (high $-16.22M, low $-25.278M), average net income is $-151M (high $-102M, low $-240M), average SG&A $18.77M (high $28.86M, low $13.73M), and average EPS is $-2.687 (high $-1.697, low $-4.618). CLDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.95M (high $3.03M, low $1.41M), average EBITDA is $-1.95M (high $-1.412M, low $-3.026M), average net income is $-224M (high $-138M, low $-389M), average SG&A $10.41M (high $16.16M, low $7.54M), and average EPS is $-3.382 (high $-2.074, low $-5.872).

Did the CLDX's actual financial results beat the analysts' financial forecasts?

Based on Celldex Therapeutics's last annual report (Dec 2023), the company's revenue was $6.88M, beating the average analysts forecast of $2.96M by 132.32%. Apple's EBITDA was $-141M, beating the average prediction of $-21.498M by 557.87%. The company's net income was $-141M, missing the average estimation of $-157M by -9.92%. Apple's SG&A was $30.91M, beating the average forecast of $15.82M by 95.39%. Lastly, the company's EPS was $-2.919K, beating the average prediction of $-2.694 by 108253.50%. In terms of the last quarterly report (Dec 2023), Celldex Therapeutics's revenue was $4.13M, beating the average analysts' forecast of $1.44M by 186.59%. The company's EBITDA was $-32.171M, beating the average prediction of $-1.441M by 2131.88%. Celldex Therapeutics's net income was $-50.252M, beating the average estimation of $-48.643M by 3.31%. The company's SG&A was $8.83M, beating the average forecast of $7.7M by 14.74%. Lastly, the company's EPS was $-1.037K, beating the average prediction of $-0.734 by 141257.41%